Effective therapies remain limited for patients with high-risk recurrence after hepatocellular carcinoma (HCC) resection. Here, the authors report a clinical trial investigating the adjuvant combination of the anti-PD-L1 antibody benmelstobart plus the multi-targeted tyrosine kinase inhibitor anlotinib, in patients with high-risk recurrence after resection of HCC.
- Xiaohui Duan
- Dongde Wu
- Xianhai Mao
